Moleculin Biotech begins Phase 2 study evaluating WP1066

Moleculin Biotech announced the commencement of an Investigator-initiated Phase 2 study evaluating WP1066 in combination with radiation therapy for the treatment of adults with glioblastoma, or NU 21C06, in cooperation with the Company. The study is being conducted under Northwestern University’s Investigative New Drug application, or IND, which cross references the Company’s own IND, which received clearance from the FDA in April 2022. This trial is funded by the National Institutes of Health, or NIH, and BrainUp, a non-profit organization dedicated to bringing awareness to brain cancer. The NU 21C06 trial is a Phase 2, open-label, multi-arm trial of radiation therapy in combination with WP1066 in newly diagnosed IDH (isocitrate dehydrogenase) wild-type, MGMT-unmethylated glioblastoma patients. The primary outcome measure for the study is progression-free survival and secondary outcome measures include tumor microenvironment analysis.